Hormonal
High-intensity aerobic exercise stimulates mTOR phosphorylation (Ser2448) early in recovery (0.5h), which correlates with sustained myofibrillar protein synthesis, whereas low-intensity exercise does not.
High-intensity aerobic exercise triggers the mTOR signaling pathway early in recovery, which is linked to sustained muscle protein synthesis. Low-intensity exercise does not trigger this specific early signaling response to the same degree. This suggests that intensity is a key driver of the molecular environment for muscle growth after cardio.
There was a significant difference at 0.5 h postexercise between the HIGH and LOW trials for phospho-mTORSer2448 (P < 0.005)... Myofibrillar FSR in early and late recovery after HIGH exercise was positively correlated with phospho-mTORSer2448 at 0.5 h postexercise (r > 0.953, P < 0.001 and r > 0.866, P < 0.01, respectively).
Why this rating
Strong correlation data and clear group differences, but limited by small sample size and single time point for the key signaling event.
Source
Influence of aerobic exercise intensity on myofibrillar and mitochondrial protein synthesis in young men during early and late postexercise recovery
Danielle M. Di Donato et al. · American Journal of Physiology-Endocrinology and Metabolism · 2014
DOI 10.1152/ajpendo.00487.2013
More from this paper
- High-intensity aerobic exercise (60% Wmax) sustains myofibrillar protein synthesis (MyoPS) into late recovery (24-28h), whereas low-intensity exercise (30% Wmax) does not, despite both stimulating early recovery MyoPS.Good
- High-intensity aerobic exercise stimulates mitochondrial protein synthesis (MitoPS) in late recovery (24-28h), whereas low-intensity exercise does not, although neither intensity stimulated MitoPS in early recovery (0.5-4.5h) in the fasted state.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →